UNIQURE N.V.
QURELoading price...
Overview
Previous Close26.99
Open43.63
Ask54.56
Bid34.85
Day's Range42.50 - 49.06
52 Week Range8.73 - 71.50
PE Ratio(TTM)--
Market Cap3.09B
Volume16.72M
Avg. Volume1.75M
12 Months Earnings-208.87M
12 Months Revenue18.09M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 18.09M | 16.10M | 27.12M | 15.84M | 106.48M |
| Cost of Revenue | 1.71M | 1.69M | 18.33M | 13.63M | 3.34M |
| Gross Profit | 16.39M | 14.41M | 8.79M | 2.21M | 103.14M |
| Operating Expenses | 211.11M | 202.24M | 190.97M | 284.70M | 247.39M |
| Profit after Tax (Net Income) | -208.87M | -198.97M | -239.56M | -308.48M | -126.79M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Amsterdam, Netherlands
Website: https://www.uniqure.com
CEO & Executive Director: Mr. Matthew Craig Kapusta CPA
Employees: 221
About Company:
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.